For Genzyme, the wild ride continues

A virus, plant shutdown, FDA consent decree, Carl Icahn, and finally Sanofi-Aventis--what a ride it's been for Genzyme. But the rollercoaster has yet to come to a stop. Sanofi CEO Christopher Viehbacher says changes are coming to Genzyme as a result of the merger. "It wouldn't be credible to say there aren't going to be some cost savings along the way,'' he tells the Boston Globe. Story

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.